Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors
NCT05010096 · M.D. Anderson Cancer Center · PHASE1 · withdrawn · last registry update 2022-05-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No participants Enrolled” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3CA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-05-17Phase 3 first posted: Hoffmann-La Roche, Ipatasertib + Tiragolumab (NCT05862285)
- 2023-05-10Also stopped (terminated): Peter MacCallum Cancer Centre, Australia, Trametinib + Cobimetinib (NCT04801966)
- 2023-04-27Also stopped (withdrawn): Roswell Park Cancer Institute, Buparlisib + Cisplatin (NCT01971489)
- 2023-02-28Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride (NCT05490771)
- 2022-12-28Results posted on the registry: National Cancer Institute (NCI), Taselisib (NCT04439175)
- 2022-12-27Also stopped (withdrawn): Pamela Munster, Alpelisib + Carboplatin (NCT05472220)
- 2022-12-14Results posted on the registry: Memorial Sloan Kettering Cancer Center, Copanlisib + Ibrutinib (NCT03877055)
- 2022-12-12Phase 3 first posted: Hoffmann-La Roche, Inavolisib + Fulvestrant (NCT05646862)
- 2022-11-28Also stopped (terminated): UNICANCER, Alpelisib + Chemotherapy (NCT03386162)
- 2022-09-26Also stopped (terminated): Jonsson Comprehensive Cancer Center, Copanlisib + Letrozole (NCT03128619)
- 2022-08-22Also stopped (terminated): Vanderbilt-Ingram Cancer Center, Enzalutamide + Taselisib (NCT02457910)
- 2022-08-16Phase 3 first posted: Celcuity Inc, Gedatolisib + Palbociclib (NCT05501886)
- 2022-08-01Also stopped (terminated): Novartis Pharmaceuticals, LSZ102 + LEE011 (NCT02734615)
- 2022-07-28Also stopped (withdrawn): Rutgers, The State University of New Jersey, BKM120 + Nabpaclitaxel (NCT02117817)
- 2022-07-12Also stopped (terminated): Hoffmann-La Roche, Taselisib + Placebo (NCT02340221)
- 2022-07-08Results posted on the registry: Fox Chase Cancer Center, MK-3475 + Copanlisib (NCT02535247)
- 2022-07-08Also stopped (terminated): Fox Chase Cancer Center, MK-3475 + Copanlisib (NCT02535247)
- 2022-05-18Also stopped (terminated): SignalRX Pharmaceuticals, Inc., SF1126 + Nivolumab (NCT03059147)
- 2022-04-11Results posted on the registry: University of Washington, Copanlisib + Rituximab (NCT04155840)
- 2022-04-11Also stopped (terminated): University of Washington, Copanlisib + Rituximab (NCT04155840)
- 2022-04-01Also stopped (terminated): Swiss Cancer Institute, Copanlisib + Venetoclax (NCT03886649)
- 2022-02-01Results posted on the registry: US Oncology Research, BKM120 + capecitabine (NCT02000882)
- 2022-01-04Results posted on the registry: Bayer, Copanlisib (Aliqopa, BAY80-6946) + Placebo (NCT02367040)
- 2021-10-11Also stopped (terminated): Prince of Songkla University, BKM120 (NCT01806649)
- 2021-10-07Results posted on the registry: Pfizer, PF-05212384 (gedatolisib) + Docetaxel (NCT01920061)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision